GUGGENHIME ANDREW sold $539K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $53.89 ($53.76–$54.18, $0.54M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CFO’s open-market sale of 10,000 shares at an average price of about $53.89 under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment monitoring, but the 10b5-1 framing suggests limited informational content.
What to watch
The article does not state whether sales were part of a larger scheduled program, nor does it include any offsetting insider buys or new company fundamentals.
Background
This is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte insider Andrew Guggenheim, President and CFO, sold about $539K of PCVX shares via a 10b5-1 plan on Aug. 3.
Likely limited near-term impact; treat as non-informational unless corroborated by other company-specific news.
The filing is a Form 4 open-market sale under a pre-arranged 10b5-1 plan, which typically reduces signaling value versus discretionary sales.
Market effects
Minimal; this is company-specific insider activity without sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal expectations of near-term volatility or liquidity needs.
Key entities
- issuerVaxcyte, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderAndrew Guggenheim
President and CFO who sold shares via a 10b5-1 plan.
